[Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy].
Combination chemotherapy including carboplatin was administered intraarterially from the internal iliac artery as neoadjuvant chemotherapy to nine patients with advanced uterine cervical cancer. Two or three courses were repeated at intervals of 3 weeks. And to investigate whether the administration of Lipo PGE1 with the action of vasodilation before intra-arterial chemotherapy increases tissue levels of anticancer agents, 7 out of 9 patients were treated with Lipo PGE1, followed by arterial infusion chemotherapy. After infusion, tissue platinum (Pt) concentrations were measured by flameless atomic absorption spectrophotometry. Three of 9 patients with measurable tumor had a complete response and 6 had a partial response. Tissue Pt concentrations reached maximum levels 2-6 hours after intra-arterial chemotherapy. Tissue Pt levels of the patients with pretreatment of Lipo PGE1 were significantly higher than those without pretreatment (p < 0.01). It seems likely that Lipo PGE1 administration before intra-arterial chemotherapy is useful for the enhancement of tissue levels of anticancer agents as well as the clinical effects.
Takeda
S
S
Dept. of Obstetrics and Gynecology, Saitama Medical Center, Saitama Medical School.
Ikeba
K
K
Ohokubo
T
T
Sodemoto
T
T
Yamamoto
T
T
Takagi
A
A
Hayashi
N
N
Kinoshita
K
K
D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism; D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism; D002584:Cervix Uteri / Q000737:chemistry*; D017024:Chemotherapy, Adjuvant; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007083:Iliac Artery; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010984:Platinum / Q000032:analysis*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014751:Vindesine / Q000008:administration & dosage
D001761:Bleomycin; D015251:Epirubicin; D010984:Platinum; D016685:Mitomycin; D005047:Etoposide; D016190:Carboplatin; D000527:Alprostadil; D014751:Vindesine